Shares of Spirit Airlines, Inc. (NYSE: SAVE) experienced a dip in pre-market trading as it revised downwardly its third-quarter 2023 outlook. The company now anticipates revenues between $1.245 billion and $1.255 billion, a notable decrease from its earlier projection of $1.300 billion to $1.320 billion. This adjustment falls short of the consensus estimate of $1.32 billion for the same period.

$SAVE was trading at $16.65 in pre-market, reflecting a decrease of $0.63 or 3.65%.

In other news, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a prominent RNAi therapeutics company, had its common stock trading halted by NASDAQ today. This action comes as the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee convenes at 9:00 a.m. ET to review the supplemental New Drug Application for patisiran, an investigational RNAi therapeutic designed for treating the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.

As previously disclosed, the FDA has established an action date of October 8, 2023, in accordance with the Prescription Drug User Fee Act. 

$ALNY closed at $211.65 on Tuesday, marking a notable gain of $7.93 or 3.89%, ahead of the FDA's panel meeting.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)